News
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a potential long-term growth.
Stock futures were falling Tuesday and oil prices rose as Israel and Iran continued to exchange missile attacks and President ...
Global stock markets face uncertainty as Israel-Iran conflict impacts investor confidence, causing shifts in energy stocks ...
The rumored acquisition represents a natural progression of the existing partnership between Eli Lilly and Verve Therapeutics that began in mid-2023. Initially focused on advancing Verve’s in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback